Staar Surgical Co. shares jumped 18 percent on Thursday after the vision products company moved from a loss to profit in the second quarter amid growing overseas demand for one of its implantable corrective eye lenses.
The Monrovia company reported net income of $278,000 (1 cent a share), compared with a net loss of $491,000 (-1 cent) in the same period a year earlier. Revenue rose 14 percent to $18.2 million, $11.3 million coming from sales of its Visian ICL lens, which treats nearsightedness.
In a conference call with analysts, Chief Executive Barry Caldwell said that despite “headwinds” from unfavorable currency exchange rates, sales of the Visian ICL soared 77 percent in China, and rose 7 percent in South Korea, its two largest ICL revenue markets in the quarter.
Shares closed up $1.90, or 18 percent, to $12.41 on the Nasdaq, making the stock the biggest gainer Thursday on the Los Angeles Business Journal Stock Index.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Staar Surgical Jumps on Revenue Improvement
- Sales of Staar's Visian ICL Climb
- Staar Surgical Strikes Deal With Japanese Eye Clinic
- Staar's Stock Price Surging On OK of Medical Devices
- Staar Surgical Misses Wall Street Profit Estimates
- Staar Receives Two Overseas Approvals for Visian
- Staar Jumps on Better-Than-Expected Revenue
- Seeing Brighter Future